Argent BioPharma Expands Pipeline with Promising Drug CimetrA®

Rhea-AI Summary

Argent BioPharma (ASX: RGT, OTCQB: RGTLF) has announced positive Phase IIb clinical trial results for its novel anti-inflammatory treatment, CimetrA®. The trial demonstrated significant benefits in COVID-19 patients, including:

• No drug-related adverse events
• Faster clinical improvement compared to placebo (WHO Ordinal Scale)
• Reduced inflammation with modulation of key markers (IL-6, IL-1β, TNF-α)
• Improved quality of life trends

The company is also developing CannEpil®, an oral mucosal solution with high-CBD and low-THC formulation, designed for severe epilepsy treatment. The drug is currently making progress in the UK market.

Positive

• Successful Phase IIb trial results for CimetrA with no drug-related adverse events
• Demonstrated clinical efficacy in COVID-19 treatment with faster recovery times
• Proven modulation of multiple inflammatory markers
• Pipeline expansion with two promising drugs: CimetrA and CannEpil
• Market entry progress in UK for CannEpil

Negative

• Early-stage development status (Phase IIb) indicates long pathway to full approval
• Focused on competitive COVID-19 treatment market

PERTH, Australia, March 16, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.

Key Findings:

• No drug-related adverse events, reinforcing CimetrA®'s safety.
• Faster clinical improvement versus placebo, measured by the WHO Ordinal Scale.
• Reduced inflammation, with significant modulation of key inflammatory markers (IL-6, IL-1β, TNF-α, and more).
• Improved quality of life trends observed in CimetrA®-treated patients.

CEO Roby Zomer stated:
"These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development."

With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil®, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpil® is making waves in the UK as part of a movement to transform severe epilepsy treatment. This further reinforces Argent BioPharma's commitment to addressing global health challenges.

For further information, please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

View original content:https://www.prnewswire.com/news-releases/argent-biopharma-expands-pipeline-with-promising-drug-cimetra-302402507.html

SOURCE Argent BioPharma Ltd.

FAQ

What were the key findings of RGTLF's CimetrA Phase IIb trial?

The trial showed no drug-related adverse events, faster clinical improvement vs placebo, reduced inflammation markers, and improved quality of life trends in COVID-19 patients.

How does Argent BioPharma's CimetrA medication work against COVID-19?

CimetrA works as an anti-inflammatory treatment, modulating key inflammatory markers including IL-6, IL-1β, and TNF-α, leading to faster clinical improvement.

What is the composition of RGTLF's CannEpil epilepsy treatment?

CannEpil is an oral mucosal solution featuring a high-CBD, low-THC formulation designed to reduce seizure frequency and severity while minimizing psychoactive effects.

What markets is Argent BioPharma (RGTLF) targeting with CannEpil?

CannEpil is currently advancing in the UK market as part of efforts to transform severe epilepsy treatment.